Probucol's antioxidant effects make it a potential alternative therapy for improving atherosclerotic disease and effectively preventing carotid atherosclerosis progression in hypercholesterolemic patients (76)
BPC-157 () , -
Sikiric is named on BPC-157-related patent applications dating back to at least 1989, and Croatian government records list Predrag Sikiric as an owner of PharmaCotherapia, the company that sponsored the Tijuana trial
"Full-chain service system" Build a four-dimensional integrated model of "procurement - quality inspection - logistics - after-sales service", achieve a 72-hour rapid response mechanism, and the customer complaint rate is less than 0.5%
Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models
